At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 206 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin, Administered Orally Once Daily, in Combination With Insulin Therapy for 24 Weeks in Chinese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
In Brief
A Phase 3 clinical trial evaluating placebo, linagliptin, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 206 participants across 25 sites.
Detailed Summary
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartSep 2016
Primary CompletionJan 2019
Study CompletionJan 2019
TodayJul 2026
First PostedSep 13, 2016
Enrollment StartSep 30, 2016
Primary CompletionJan 11, 2019
Study CompletionJan 18, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.8 years ago
Interventions
placebodrug
linagliptindrug
background therapydrug
insulin with or without metformin